MX2023010002A - Biomarcadores novedosos y sus usos. - Google Patents

Biomarcadores novedosos y sus usos.

Info

Publication number
MX2023010002A
MX2023010002A MX2023010002A MX2023010002A MX2023010002A MX 2023010002 A MX2023010002 A MX 2023010002A MX 2023010002 A MX2023010002 A MX 2023010002A MX 2023010002 A MX2023010002 A MX 2023010002A MX 2023010002 A MX2023010002 A MX 2023010002A
Authority
MX
Mexico
Prior art keywords
biomarkers
agent
treatment
novel biomarkers
cancer
Prior art date
Application number
MX2023010002A
Other languages
English (en)
Inventor
Michael Cannarile
Dominik Ruettinger
Bruno Gomes
Vaios Karanikas
Theresa Kolben
Fabian Schmich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023010002A publication Critical patent/MX2023010002A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se divulgan en la presente biomarcadores novedosos para identificar pacientes con cáncer que puedan beneficiarse del tratamiento con un agente anti-CD25. También se divulgan métodos que usan dichos biomarcadores para tomar una decisión de tratamiento o monitorear el tratamiento con un agente anti-CD25, así como métodos para tratar a un paciente con cáncer que comprenden administrar un agente anti-CD25 en función del uso anterior de los biomarcadores de la presente.
MX2023010002A 2021-03-01 2022-02-28 Biomarcadores novedosos y sus usos. MX2023010002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21160004 2021-03-01
PCT/EP2022/054930 WO2022184615A1 (en) 2021-03-01 2022-02-28 Novel biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
MX2023010002A true MX2023010002A (es) 2023-09-06

Family

ID=74853536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010002A MX2023010002A (es) 2021-03-01 2022-02-28 Biomarcadores novedosos y sus usos.

Country Status (12)

Country Link
US (1) US20240094212A1 (es)
EP (1) EP4302092A1 (es)
JP (1) JP2024507972A (es)
KR (1) KR20230154012A (es)
CN (1) CN116940844A (es)
AU (1) AU2022228640A1 (es)
BR (1) BR112023017638A2 (es)
CA (1) CA3209636A1 (es)
IL (1) IL304313A (es)
MX (1) MX2023010002A (es)
TW (1) TW202303147A (es)
WO (1) WO2022184615A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3765503B1 (en) 2018-03-13 2024-05-01 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion

Also Published As

Publication number Publication date
IL304313A (en) 2023-09-01
BR112023017638A2 (pt) 2023-10-10
CA3209636A1 (en) 2022-09-09
KR20230154012A (ko) 2023-11-07
AU2022228640A1 (en) 2023-07-20
EP4302092A1 (en) 2024-01-10
WO2022184615A1 (en) 2022-09-09
TW202303147A (zh) 2023-01-16
US20240094212A1 (en) 2024-03-21
JP2024507972A (ja) 2024-02-21
CN116940844A (zh) 2023-10-24

Similar Documents

Publication Publication Date Title
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2022008868A (es) Tratamiento del cancer con tg02.
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
WO2015148389A3 (en) Diagnosis of multiple sclerosis in human and animal subjects
MX2021002006A (es) Tratamiento del cancer de mama triple negativo con inhibicion dirigida del factor de crecimiento transformante beta (tgf-b).
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA202092540A1 (ru) Комбинации для лечения рака
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2022016061A (es) Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
MX2023006598A (es) Biomarcadores agonistas del trem2 y métodos para usarlos.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
EA202090558A1 (ru) Схемы лечения
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
MX2023010002A (es) Biomarcadores novedosos y sus usos.
CR20210029A (es) MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
WO2023009834A3 (en) Methods of treating cancer
MX2016003525A (es) Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.